Castle Biosciences, Inc. (CSTL) 股票分析

公司概述

Castle Biosciences, Inc. operates as a molecular diagnostics company that provides specialized test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The firm functions within the Healthcare sector, specifically targeting the Diagnostics & Research industry, which positions it to leverage advancements in gene expression profiling for clinical decision-making. The company currently maintains a market capitalization of $709.83M and employs 883 individuals to support its operational footprint. Its reported annual revenue of $344.23M indicates a mid-sized market presence that relies heavily on the adoption of its proprietary gene expression profiles, such as DecisionDx-Melanoma, to generate income streams in a competitive medical testing landscape.

财务健康

Castle Biosciences reported a trailing twelve-month revenue of $344.23M, yet this generated a net income loss of $24.158M and an EBITDA of $-2.039M, revealing a significant cost structure where operating expenses substantially exceed gross profit margins. Despite the accounting losses, the company generated positive free cash flow of $41.21M, which provides essential financial flexibility to fund research and development or manage liquidity without immediate external financing. The company exhibits a gross margin of 79.4%, suggesting high pricing power on its core diagnostic products, though this is offset by an operating margin of -4.4% and a profit margin of -7.0%, indicating that overhead costs and R&D expenditures are eroding bottom-line profitability. The balance sheet is characterized by $299.50M in cash assets against $37.02M in debt, resulting in a debt-to-equity ratio of 7.86, which technically suggests a leveraged classification but is heavily mitigated by the substantial cash reserves. A current ratio of 5.26 demonstrates robust short-term liquidity, ensuring the firm can comfortably meet its obligations as they come due. Furthermore, the return on equity stands at -5.2% and the return on assets is -2.6%, metrics that reflect the company's current phase of investment where capital is being deployed to generate future earnings rather than producing immediate returns.

估值评估

The valuation metrics present a complex picture with a P/E ratio (TTM) listed as N/A due to the net loss, while the forward P/E is calculated at -43.09, implying that the market does not yet assign a positive earnings multiple based on current trailing performance. The price-to-book ratio is 1.48, indicating that the market values the company at a 48% premium over its book value, likely reflecting the intangible value of its intellectual property and pipeline potential. Alternative valuation measures such as a price-to-sales ratio of 2.06 and an EV/EBITDA of -212.90 suggest that investors are pricing the stock based on revenue growth potential and asset backing rather than current profitability. The stock's 52-week trading range spans from a low of $14.59 to a high of $44.28, providing a historical context for price volatility and investor sentiment over the past year. With a beta of 1.19, the stock demonstrates volatility that is slightly higher than the broader market, meaning it tends to move with greater magnitude than the overall index during periods of market fluctuation.

Growth & Income

The company recorded a revenue growth of 0.8% year-over-year, while earnings growth is listed as N/A due to the lack of profitability, suggesting that the top-line expansion is not yet translating into bottom-line gains. Castle Biosciences does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company retains all earnings to reinvest into its diagnostic product lines and research initiatives rather than distributing cash to shareholders. This retention strategy is typical for biotechnology firms in the early commercialization phase where capital allocation focuses on sustaining operations and advancing clinical programs. The overall growth and income profile is defined by steady but modest revenue expansion coupled with an absence of dividend income, positioning the stock primarily as a growth vehicle dependent on future profitability milestones.